Purepac
Executive Summary
Has marketed a generic version of Warner-Lambert's Eryc since August. Purepac's parent Faulding is the innovator of the delayed- release erythromycin product, which it exclusively licensed to Warner-Lambert until August. Purepac said it has experienced a significant increase in demand for the erythromycin product since Warner-Lambert and Barr Labs suspended distribution of their products due to manufacturing difficulties ("The Pink Sheet" May 10, T&G-10).